Analysis of enzymes to use for the modification of fucoidan

岩藻依聚糖是一种在褐藻（海藻）中发现的多糖。ARC医疗器械公司制定并 销售从褐藻中提取和纯化的褐藻多糖硫酸酯，用于外科手术后的兽医用途，以减少粘连 发展这非常有效，促使人们希望开发用于人类的产品。的 然而，对这一点的挑战是岩藻依聚糖是一种非常大的非均相组成分子， 使得难以a）满足医用材料所需的更高的纯度和均匀性标准， 用于人类受试者和B）以人类试验所需的量进行。 我们提出的解决方案是利用海洋细菌中天然存在的酶， 生物加工酶来调整岩藻依聚糖的结构和大小，和/或合成岩藻依聚糖片段， 该材料具有更明确的尺寸和组成，并且最终可以大量获得， 高纯度为实现这一目标而设想的途径有多个步骤，其具体目标是 该建议是实现产生酶促工具所需的初始和关键步骤， 重构和/或合成岩藻依聚糖。 该项目的成功完成将导致生产一种新型的一流医疗器械的过程 用于减少人类手术后粘连，这反过来将减少疼痛，痛苦，不孕症和 普通外科手术后加拿大患者的死亡率;减少加拿大住院时间， 再次入院和再次手术，这反过来将降低加拿大政府的医疗保健成本， 纳税人;并在加拿大境内创造科学，制造和销售工作。

Fucoidan is a polysaccharide found in brown algae (seaweed). ARC Medical Devices Inc. has developed and markets fucoidan extracted and purified from brown algae for post-surgical veterinary use to reduce adhesion development. This works very effectively, prompting a desire to develop the product for use in humans. The challenge to this, however, is that fucoidan is an extremely large molecule of heterogeneous composition, making it difficult to a) meet the higher standards of purity and homogeneity required of medical materials for use in human subjects and b) do so in quantities required for human trials. Our proposed solution is to harness naturally occurring enzymes found in marine bacteria and use these bio-processing enzymes to tailor the structure and size of fucoidan, and/or synthesize fucoidan fragments, such that the material is of more defined size and composition and can ultimately be obtained in large quantities of high purity. The pathway envisioned to achieve this has multiple steps, with the particular objective of this proposal being to achieve the initial and critical steps of generating the enzymatic tools required to enable the remodeling and/or synthesis of fucoidan. Successful completion of the project will result in a process to produce a novel, first in class medical device for the reduction of post-surgical adhesions in humans, which in turn will reduce pain, suffering, infertility and mortality in Canadian patients following common surgical procedures; reduce Canadian hospital stays, hospital re-admissions, and re-operations, which in turn will reduce healthcare costs for Canadian governments and taxpayers; and create scientific, manufacturing and sales jobs within Canada.